>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>S-trityl-L-Cysteine

S-trityl-L-Cysteine (Synonyms: NSC 83265)

Catalog No.GC40932

S-트리틸-L-시스테인(NSC 83265)은 기본 ATPase 활성 억제에 대한 IC50이 1μM이고 미세소관 활성화 ATPase 활성에 대해 140nM인 선택적 알로스테릭 키네신 Eg5 억제제입니다. S-트리틸-L-시스테인은 항종양 활성이 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

S-trityl-L-Cysteine Chemical Structure

Cas No.: 2799/7/7

Size 가격 재고 수량
1g
US$25.00
재고 있음
5g
US$80.00
재고 있음
10g
US$148.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

S-trityl-L-Cysteine is a non-natural amino acid and an inhibitor of Eg5, also known as KSP and Kif11, a mitotic kinesin necessary for mitotic spindle formation. S-trityl-L-Cysteine inhibits the ATPase activity of Eg5 in basal and microtubule-stimulated states (IC50s = 1,000 and 140 nM, respectively). It is selective for Eg5 over nine other human kinesins in an enzyme-coupled assay. It reversibly inhibits Eg5-driven microtubule sliding velocity with an IC50 value of 500 nM using X. laevis recombinant Eg5. It induces cell cycle arrest in HeLa cells (IC50 = 700 nM), reversibly halting the cell cycle in the mitotic phase by inhibiting the separation of duplicated chromosomes and preventing bipolar spindle formation. S-trityl-L-Cysteine inhibits the growth of cancer cells in vitro when tested against the National Cancer Institute (NCI) 60 human cancer cell line panel (average GI50 = 1.3 µM) and in mouse xenograft models.

리뷰

Review for S-trityl-L-Cysteine

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for S-trityl-L-Cysteine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.